CA
BCRX icon

Cetera Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cetera Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-18,155
Closed -$295K – 1374
2022
Q1 		$295K Buy
+18,155
New +$291K 0.01% 1112

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Advisors's BCRX Position: Q2 2022 in Review

Cetera Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 18,155 shares — an estimated $295K sold.

Cetera Advisors first reported a position in BCRX in Q1 2022 and held it in 1 quarter. The position peaked at $295K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

  • Cetera Advisors reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cetera Advisors sold 18,155 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $295K.
  • Cetera Advisors first reported a position in BioCryst Pharmaceuticals in Q1 2022 and held it in 1 quarter.
  • Cetera Advisors's BioCryst Pharmaceuticals position peaked at $295K in Q1 2022.
  • 221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on Cetera Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.